A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
DOSCORT is a 2-dose, cross-over study primarily aiming to identify and validate novel
biological markers (biomarkers) of glucocorticoid effect in the human body. Patients with
Addison´s disease, primary adrenal insufficiency, with life-long glucocorticoid replacement
therapy will undergo 2 treatment periods where their usual hydrocortisone treatment will be
replaced with betamethasone in physiological and supra physiological doses. Blood, saliva,
urine, health related Quality-of-life self-assessment forms, measurements of physical
activity and sleep quality will be collected from both treatment periods.